Insilico Medicine uses generative AI for drug discovery and has set the trend for AI in the pharmaceutical industry. They have developed an AI platform to identify novel targets and molecules, significantly reducing the time and cost of the drug discovery process. The company has a pipeline of novel molecules and drugs, with one asset in clinical trials for idiopathic pulmonary fibrosis (IPF). They’ve gained the trust of the pharma industry and have partnerships with big pharma and contract research organizations.

Story Notes:

• Introduction and Background of Insilico Medicine
• Understanding Generative AI
• Insilico Medicine's Approach to Drug Discovery
• The Visionary Leadership of Alex Zhavoronkov

To learn more, visit:
https://boldcapitalpartners.com/